[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tobacco-use\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tobacco-use":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,43,69,87,115,149,171,194,229,256,276,300,319,343,370,395,425,457,478,502,529,551,584,604,624],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100642355","impact-of-electronic-cigarette-temperature-and-solvent-on-biomarkers-100642355",false,"NCT07612696","Impact of Electronic Cigarette Temperature and Solvent on Biomarkers","Clinical Study on the Impact of Electronic Cigarette Temperature and Solvent on Biomarkers of Oxidant Exposure","Inclusion Criteria:\n\n* 21 years of age or older\n* Normal pulmonary and cardiovascular function with no history of COPD or cardiovascular disease (excluding hypertension)\n* Current exclusive use of a sub-ohm\u002Fmod or pod EC devices (≥ 1mL e-liquid\u002Fper day, ≥6 mg\u002Fml nicotine concentration, EC for ≥ 1 year)\n* No plan on quitting nicotine use over the course of the study\n* All other forms of nicotine must be used \\\u003C5 days out of the past 28 days.\n* Able to read and write in English\n* Have access to email and a smartphone\u002Fcomputer that has reliable internet connection\n\nExclusion Criteria:\n\n* Women who are pregnant and\u002For nursing or trying to become pregnant\n* Unstable or significant medical condition in the past 3 months (e.g., recent heart attack or other serious heart condition, stroke, severe angina)\n* Respiratory diseases (e.g., exacerbations of asthma or COPD, require oxygen, require oral prednisone), kidney (e.g., dialysis) or liver disease (e.g., cirrhosis), severe immune system disorders (e.g., uncontrolled HIV\u002FAIDS, multiple sclerosis symptoms) or any medical disorder\u002Fmedication that may affect participant safety or biomarker data\n* Uncontrolled substance abuse or inpatient treatment for that condition in the past 6 months\n* Have immediate family or household members currently participating in this trial","ALL","21 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This project seeks to determine how e-cigarette (EC) physical design features, including those that allow the user to manipulate the quality and quantity of aerosols, affect exposure and toxicity from oxidants and other aerosol constituents.",[27,28,29],"Oxidative Stress","Tobacco Use","Electronic Cigarettes","NOT_YET_RECRUITING","2026-06-12",{"date":33,"type":34},"2026-06-16","ACTUAL",{"date":36,"type":21},"2026-07-15",{"date":38,"type":21},"2028-12",{"name":40,"class":41},"Milton S. Hershey Medical Center","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100601259","symptoms-and-functions-in-patients-with-copd-and-chronic-bronchitis-switching-from-cig-to-ths-100601259","NCT07108166","Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS","A Randomized, Single (Operator)-Blinded, Controlled Clinical Study for Assessing Major Symptoms and Function in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis Who Switch From Combustible Cigarettes (CIG) to Tobacco Heating System (THS)","Inclusion Criteria:\n\n* Adult, both sexes, aged ≥ 40 years.\n* Patient has read, understood, and signed the written informed consent form (ICF), which has received IEC or IRB approval.\n* Patient with body mass index (BMI) 17.6-40.0 kg\u002Fm2 and body weight \\> 50 kg (male) or \\> 40 kg (female). Checked at V1 and V2.\n* Patient has a CIG smoking history ≥ 10 years.\n* Patient has been smoking ≥ 10 commercially available and\u002For roll-your-own CIG\u002Fday on average (no brand restriction) for at least the last year (based on self-reporting). Smoking status will be verified by Urine cotinine test (UCOT) ≥200 ng\u002FmL. Intermittent CIG smoking abstinence, with or without Smoking Cessation Treatment during these attempts, not exceeding 10 days total within the past year will be allowed. Checked at V1 and V2.\n* Patient has been advised to quit smoking, informed of smoking risks and of cessation programs as per SoC at V2, and is not willing to quit CIG use for the study duration. Checked at V1 and V2.\n* Patient agrees to be randomized into one of the two study arms. Checked at V2.\n* Patient with confirmed COPD via spirometry performed at V1 (FEV1\u002FFVC \\\u003C70%, post-bronchodilator (-BD)) and COPD severity classified by the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) as GOLD 2 or 3 (30%≤ FEV1 \\\u003C 80% predicted, -BD) with presence of chronic bronchitis (cough and mucus most of the days for \\> three months a year for the two consecutive years prior to the screening visit). Checked at V2.\n* Patient has cough frequency of ≥ 10 cough\u002Fhour during daytime from objective count sensor applied at V1, used to verify eligibility at V2. (Daytime is defined as occurring between 07:00:00 and 22:59:59, based on the local time zone of the site where the patient is assessed.)\n\nExclusion Criteria:\n\n* Patient who self-report concomitant daily use of inhaled cannabis or any type of nicotine containing products other than CIG within the last year.\n* Patient with COPD (moderate or severe) exacerbation that has not resolved according to the GOLD standard (e.g., requirement of additional therapy) or investigator's discretion. Checked at V1 and V2.\n* Patient with currently active cancer or history of any cancer within the last 5 years prior to V1, except for those with basal cell carcinoma of the skin.\n* Patient with acute worsening symptoms of chronic bronchitis or other active respiratory or systemic infections that have not resolved. Checked at V1 and V2.\n* Patient with medical condition(s) that would jeopardize his(her) safety in the context of this study (e.g., safety laboratory parameters, abnormal ECG) or with a condition that would jeopardize study results (e.g., gastroesophageal reflux disease (GERD), heart failure, severe chronic lung emphysema, active symptomatic hay fever), as per Investigator's discretion. Checked at V1 and V2.\n* Patient is legally incompetent, physically, and\u002For mentally incapable of giving consent (e.g., emergency situation, under guardianship, in a social or sanitary establishment, prisoner or involuntarily incarcerated, unable to read).\n* Patient with a history of asthma.\n* Employee of the investigational site or any other party involved in the study, or their first-degree relatives (parent, child, spouse).\n* Current or former employee of the tobacco or e-cigarette industry or their 1st-degree relatives.\n* Patient with active or history of alcohol and\u002For drug abuse within the past year.\n* Patient with positive serological tests for human immunodeficiency virus (HIV) 1\u002F2, hepatitis B or C (Hep B\u002FC).\n* Patient with any concomitant issues (e.g., medical, psychiatric, and\u002For social reason) that, as per Investigator's discretion, would place the study patient at an unacceptable risk for participation in the study.\n* Patient who participated in any trial (for investigational medicine, or other type of intervention) that may have interfered with COPD disease progression and symptoms (including cough and dyspnea) within the last three months as per investigator's discretion.\n* Patient using any systemic (injectable or oral) corticosteroids (acute or chronic treatments) or oxygen therapy in the last 2 months excluding short term use for a COPD exacerbation.\n* Patient currently being treated with angiotensin-converting enzyme (ACE) inhibitors or opioids, or those who have used ACE inhibitors within 4 weeks or opioids within 1 week prior to screening. Checked at V1 and V2.\n* Patient treated with biologic therapies for COPD (e.g., Dupilumab) in the last 6 months.\n* Female patient is pregnant, breastfeeding or lactating, or anticipating becoming pregnant withing the duration of the study. Checked at V1 and V2.\n* Female of childbearing potential who is capable of getting pregnant, defined as a female patient who does not agree to use an acceptable method of effective contraception during the entire study, a female patient that is not surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year). Checked at V1 and V2.","40 Years",{"count":52,"type":21},290,[24],"The purpose of this randomized study is to demonstrate direct clinical benefit, i.e., observed benefits in how humans with COPD feel in terms of symptoms (e.g., cough frequency, shortness of breath, and other respiratory symptoms) and function (e.g., lung function, and six-minute walking test \\[6MWT\\]) after switching to THS compared to continuing to smoking cigarettes.",[56,57,28],"COPD","Smoking","RECRUITING",{"date":60,"type":34},"2026-06-15",{"date":62,"type":34},"2025-04-02",{"date":64,"type":21},"2026-11",{"name":66,"class":67},"Philip Morris Products S.A.","INDUSTRY",112,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":42},"100539926","little-cigar-oxidants-100539926","NCT06310187","Little Cigar Oxidants","Oxidative Stress and Harmful Constituent Levels Associated With Little Cigars","Inclusion Criteria:\n\n1. Aged 21 - 65 years old\n2. Daily cigarette smoker (\\>= 1 cigarette per day);\n3. Smoke regular, filtered cigarettes or machine rolled cigarettes with a filter\n4. No current or past use of Little Cigars\n5. All other forms of nicotine must be used \\\u003C6 days out of the past 30 days.\n6. Able to read and write in English\n7. No serious cigarette smoking quit attempt or use of any FDA-approved smoking cessation medication in the prior 30 days\n8. No plan to quitting smoking in the next 3 months\n\nExclusion Criteria:\n\n1. Women who are pregnant and\u002For nursing or trying to become pregnant\n2. Unstable or significant medical condition in the past 3 months (e.g., recent heart attack or other serious heart condition, stroke, severe angina)\n3. Respiratory diseases (e.g., exacerbations of asthma or Chronic Obstructive Pulmonary Disease (COPD), require oxygen, require oral prednisone), kidney (e.g., dialysis) or liver disease (e.g., cirrhosis), severe immune system disorders (e.g., uncontrolled HIV\u002FAIDS, multiple sclerosis symptoms) or any medical disorder\u002Fmedication that may affect participant safety or biomarker data\n4. Uncontrolled substance abuse or inpatient treatment for that condition in the past 6 months\n5. Exhaled Carbon Monoxide (CO) measurement of \\>= 17 parts per million","65 Years",{"count":20,"type":21},[24],"Determine the effects of little cigars on human exposure to tobacco smoke oxidants. In a balanced randomized cross-over study design in cigarette smokers, subjects will be assigned to 3 exposure groups. These include a high oxidant little cigar exposure condition, a low oxidant little cigar exposure condition, and their usual cigarette. Biological samples will be collected before and after product usage.",[28,27],{"date":33,"type":34},{"date":83,"type":34},"2026-03-25",{"date":85,"type":21},"2029-08",{"name":40,"class":41},{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":42},"100608281","catalyzing-cigarette-smoking-cessation-through-harm-reduction-sampling-among-people-unmotivated-to-quit-100608281","NCT07199517","Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit","Inclusion Criteria:\n\n1. Able to communicate fluently in English (i.e., speaking, writing, and reading)\n2. Male and female smokers who are \\> 21 years of age and self-report smoking at least 5 cigarettes (menthol and\u002For non-menthol) per day for at least the last 6 months.\n3. Have a carbon monoxide (CO) greater than or equal to 10 ppm\n4. Not using any forms of nicotine regularly other than cigarettes.\n5. Not interested in quitting smoking in the next 30 days.\n6. Capable of giving written informed consent, including compliance with the requirements and restrictions listed in the combined consent and HIPAA form\n\nExclusion Criteria:\n\nSmoking Behavior\n\n1. Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, IQOS, ONPS, etc.).\n2. Current or impending (during the study period) enrollment or plans to enroll in a smoking cessation program.\n3. Current use of smoking cessation medication.\n4. Provide a CO breath test reading less than 10 ppm at Intake.\n\nAlcohol and Drug\n\n1. History of substance abuse (other than nicotine dependence) in the past 12 months.\n2. Current alcohol consumption that exceeds 20 standard drinks\u002Fweek.\n3. Current use of recreational drugs (other than nicotine and cannabis)\n\nMedical\n\n1. Women, including all individuals assigned as \"female\" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.\n2. Serious or unstable disease within the past year (e.g. cancer, uncontrolled hypertension, cardiovascular event).\n\nPsychiatric\n\n1\\. Lifetime history of schizophrenia or psychosis.\n\nGeneral Exclusion\n\n1. Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and\u002For the study design as determined by the Principal Investigator.\n2. Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.\n3. Significant non-compliance with protocol and\u002For study design as determined by the Principal Investigator and\u002Fo. Subjects may be deemed ineligible at any point throughout the study.",true,{"count":95,"type":21},472,[24],"This study aims to investigate harm-reduction sampling in a choice format versus medicinal nicotine sampling on smoking behavior, identify mechanisms of sampling's effects, and explore moderators of these effects among a national sample of people unmotivated to quit smoking. Participants will be randomized 2:1 to choose one of two harm-reduction products (ECIG, ONP) versus a medicinal nicotine control condition (nicotine patch + lozenge, NPL), receive a 4-week starter product regimen, and then be followed for 6 months to assess use behavior.",[99,28,100],"Cigarette Smoking","Cigarette Smoking Behavior",[102,103,104,105],"cigarette smoking","harm reduction","sampling","nicotine replacement","2026-06-10",{"date":108,"type":34},"2026-06-11",{"date":110,"type":34},"2026-01-12",{"date":112,"type":21},"2030-07-31",{"name":114,"class":41},"Abramson Cancer Center at Penn Medicine",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":123,"minAge":124,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100549784","integrating-chws-into-prenatal-care-for-maternal-smoking-cessation-100549784","NCT06438549","Integrating CHWs Into Prenatal Care for Maternal Smoking Cessation","Integrating CHWs Into Prenatal Care for Maternal Smoking Cessation: A Pilot Feasibility Study","SFHOPE","Inclusion Criteria:\n\n* \\\u003C 24 weeks pregnant\n* age \\> 18 years,\n* current smokers (100 cigarettes in their lifetime and \\>3 cigarettes per day in the last 7 days; including poly-tobacco use, combining cigarettes with non-combustible products) confirmed by expired carbon monoxide (CO)\n* willing to quit smoking and set a quit date in the next 2 weeks upon enrolling\n* enrolled in prenatal care at Loma Linda University Health (LLUH) or Riverside University Health System (RUHS)\n\nExclusion Criteria:\n\n* severe mental health problems that prevent informed consent and\u002For CHW intervention\n* women who were on Nicotine Replacement Therapy (NRT) or enrolled in a cessation program within 30 days\n* unwillingness to participate in audio-recorded key informant interviews or focus groups","FEMALE","18 Years",{"count":126,"type":21},105,[24],"This develops a novel behavioral tobacco cessation program for pregnant smokers in San Bernardino County.",[28,130,131],"Tobacco Use Cessation","Tobacco Use in Childbirth",[133,134,135,136,137,138],"prevention","treatment","disparities and social inequality","tobacco use cessation","community health worker","pregnant smokers","2026-06-05",{"date":141,"type":34},"2026-06-08",{"date":143,"type":34},"2024-05-24",{"date":145,"type":21},"2027-08",{"name":147,"class":41},"Loma Linda University",2,{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":17,"minAge":124,"maxAge":76,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":148},"100562915","phase-2-neural-mechanisms-connecting-deficient-sleep-and-smoking-relapse-100562915","NCT06609369","Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse","Inclusion Criteria:\n\n* English literate\n* report heavy tobacco use (including nicotine e-cigarettes) for \\>6 months\n* meet biochemical cut off for recent cigarette smoking or e-cigarette use\n* optimal body mass index\n\nExclusion Criteria:\n\n* currently enrolled in other treatments\n* neuropsychiatric exclusions that could interfere with study participation, increase risk of adverse events, and\u002For induce deficient sleep\n* medical contraindications for fMRI, varenicline, and\u002For behavioral treatment\n* factors that cause deficient sleep and for which behavioral treatment has less benefit\n* women who are pregnant or nursing",{"count":156,"type":21},114,[158],"PHASE2","The study aims to investigate whether behavioral interventions promote cessation in adult smokers by ameliorating negative emotions and improving self-control and identify the neural markers of these effects.",[28,161,162],"Tobacco Cessation","Insomnia","2026-06-04",{"date":139,"type":34},{"date":166,"type":34},"2025-04-21",{"date":168,"type":21},"2029-06",{"name":170,"class":41},"Yale University",{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":93,"sex":17,"minAge":50,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":181,"phases":4,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100417986","lung-macrophage-populations-and-functions-in-chronic-obstructive-pulmonary-disease-copd-susceptible-smokers-100417986","NCT04722835","Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers","Pre-COPD Pilot","Inclusion Criteria:\n\n* Ages between 40 to 75 years old.\n* History of at least 20 pack-years of smoking.\n* No diagnosis of COPD or asthma.\n* No spirometric evidence of airflow obstruction as determined by FEV1\u002FFVC ratio ≥0.7.\n* FEV1 and FVC \\>lower limit of normal.\n* Less than 1 pack-year history of tobacco smoking and no tobacco use within the past 12 months.\n* Subjects will be divided into two groups by their RV\u002FTLC:\n\nNormal RV\u002FTLC Group:\n\n• Plethysmographic RV\u002FTLC equal or less than lower limit of normal.\n\nAbnormal RV\u002FTLC Group:\n\n• Plethysmographic RV\u002FTLC higher than lower limit of normal.\n\nExclusion Criteria:\n\n* Any history of IV drug use or inhalation of recreational drugs other than marijuana: A- within the past 20 years. B- more than 100 times IV drug usage. C- longer than 1 year usage.\n* Marijuana use \\>400 joints in lifetime or any within past 6 months.\n* Inability to walk briskly, run on treadmill, or pedal on ergometer to perform the study-required exercise level.\n* Pregnant\u002Fbreast feeding.\n* Serious and active heart conditions- defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy.\n* Liver cirrhosis.\n* History of chronic active Hepatitis B or C.","75 Years",{"count":180,"type":21},40,"OBSERVATIONAL","Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease that affects only a fraction of those who smoke tobacco. The origin of this variability in susceptibility to develop COPD is unclear, but understanding its underlying biology has important implications for our ability to design suitable preventative and therapeutic strategies for its management. This Department of Defense (DOD) discovery research proposes to develop methodologies and generate preliminary data needed to lay the foundation for a large study that would investigate the underlying biological susceptibility of those who smoke tobacco to develop COPD.",[184,57,28],"Copd","2026-06-01",{"date":163,"type":34},{"date":188,"type":34},"2021-03-01",{"date":190,"type":21},"2030-12-31",{"name":192,"class":41},"University of California, San Francisco",3,{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":93,"sex":17,"minAge":124,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":181,"phases":4,"briefSummary":202,"conditions":203,"keywords":210,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":42},"100557265","the-efficacy-of-conventional-screening-versus-mhealth-screening-in-early-detection-of-oral-potentially-malignant-disorders-and-oral-cancer-amongst-the-rural-population-of-varanasi-a-prospective-and-blinded-study-100557265","NCT06535867","The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study","Inclusion Criteria:\n\nPositive for any one or more of the following:\n\n* All individuals aged above 18 years positive for habits (smoking and smokeless tobacco, chewing betel leaf, areca nut, paan masala, and\u002For regular use of alcohol)\n* Clinical signs\u002Fsymptoms (non-healing ulcers, white\u002F red\u002Fred \\& white patches in the mouth, restriction of mouth opening and swelling of the neck)\n* All individuals aged above 40 irrespective of habit\u002Foral lesions\n\nExclusion Criteria:\n\n* Individuals already diagnosed with oral cancer and undergoing treatment for oral cancer\n* Under treatment for tuberculosis or suffering from any acute illness\u002F debilitating systemic disorders",{"count":201,"type":21},5122,"Mobile health (mHealth) will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers. This program is inclusive of long term surveillance to downstage oral cancer in India",[57,204,205,206,28,207,208,209],"Smoking, Cigarette","Smoking, Tobacco","Betel Chewer's Mucosa","Tobacco Smoking","Alcohol Drinking","Smokeless Tobacco Hyperkeratosis",[211,212,213,214,215,216,217,218,219,220],"smoking","smoking, cigarette","smoking, tobacco","smokeless tobacco","betel leaf","areca nut","paan masala","alcohol use","Memorial Sloan Kettering Cancer Center","24-148","2026-05-19",{"date":223,"type":34},"2026-05-22",{"date":225,"type":34},"2024-07-30",{"date":227,"type":21},"2031-07-30",{"name":219,"class":41},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":93,"sex":17,"minAge":124,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":42},"100581563","developing-a-scalable-tobacco-cessation-program-for-cancer-survivors-and-caregivers-100581563","NCT06851936","Developing a Scalable Tobacco Cessation Program for Cancer Survivors and Caregivers","Inclusion Criteria:\n\nCancer Survivors including Current Cancer Patients\n\n* Current self-reported user of any tobacco\u002Fnicotine product at time of baseline screening assessment (e.g., cigarettes, e-cigarettes, cigars, dip\u002Fchew) in the past month.\n* Any history of cancer diagnosis. Subjects currently receiving cancer-related treatments are eligible for enrollment.\n* Receiving care from the participating UF Health clinics (Medical Oncology, Urology, and Radiation Oncology).\n* Capable of completing study requirements\n* Informed consent obtained from the subject and documentation of subject agreement to comply with all study-related processes\n* Adults aged ≥18 years\n\nInformal Caregivers\u002FFamily Members of Cancer Survivors\n\n* Current self-reported user of any tobacco\u002Fnicotine product at time of baseline screening assessment (e.g., cigarettes, e-cigarettes, cigars, dip\u002Fchew) in the past month.\n* A family member, informal caregiver, or friend of an enrolled cancer survivor receiving care from the participating UF Health clinics as described above\n* Capable of completing study requirements\n* Informed consent obtained from the subject and documentation of subject agreement to comply with all study-related processes\n* Adults aged ≥18 years\n\nExclusion Criteria:\n\nCancer Survivors including Current Cancer Patients\n\n* Patients unable to complete the sessions because of language, travel or technology barriers\n* Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.\n\nInformal Caregivers\u002FFamily Members of Cancer Survivors\n\n* Participants unable to complete the sessions because of language, travel or technology barriers\n* Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.",{"count":236,"type":21},204,[24],"Given the challenges to delivering tobacco cessation treatment in oncology care and the unique challenges faced by individuals attempting to quit tobacco after a cancer diagnosis, scalable cessation programs that are tailored to the experiences of cancer survivors that also integrate caregiver\u002Ffamily support are needed. To address this need, this study will use an intervention that consists of two primary strategies: 1) a tailored cessation program for cancer survivors and family members\u002Fcaregivers who use tobacco and 2) healthcare provider training.\n\nHealthcare providers will receive training on the AAC model (Ask patients about tobacco use, Advise patients to quit, Connect patients to cessation resources), including materials focused on tobacco cessation in cancer care from the CDC, as well as a brief evidence-based communication skills training based on the C-LEAR (Counsel, Listen, Empathize, Answer, Recommend) approach.",[240,28],"Nicotine Use",[242,243,244,245,246],"tobacco cessation","AHEC","cancer survivors","tobacco","nicotine","2026-05-14",{"date":249,"type":34},"2026-05-15",{"date":251,"type":34},"2025-07-11",{"date":253,"type":21},"2026-10-21",{"name":255,"class":41},"University of Florida",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":93,"sex":17,"minAge":18,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":272,"leadSponsor":274,"locationsCount":4},"100639243","abuse-liability-of-two-modern-oral-nicotine-pouched-products-100639243","NCT07595055","Abuse Liability of Two Modern Oral Nicotine Pouched Products","An In-Clinic Confinement Study to Assess Elements of Abuse Liability of Two Modern Oral Nicotine Pouched Products","Inclusion Criteria:\n\n1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.\n3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in length as primary source of tobacco and who also use ST (e.g., moist snuff).\n4. Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of an investigator.\n5. Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand and style currently smoked most frequently by the participant.\n6. Reports daily use of ST products (i.e., moist snuff) and agrees to use the same UB ST throughout the study period. The UB moist snuff is defined as the reported moist snuff brand and style currently used most frequently by the participant.\n7. Expired breath carbon monoxide (eCO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and at check-in (Day 1).\n8. Positive urine cotinine test (i.e., ≥200 ng\u002FmL) via dipstick at Screening and at Check-in Day 1.\n9. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes\" (Heatherton et al., 1991) OR response at Screening to \"How soon after you wake up do you place your first dip?\" is either \"Within 5 minutes\" or \"6-30 minutes\" from the Fagerström Test for Nicotine Dependance-Smokeless Tobacco (FTND-ST) (Ebbert et al., 2006).\n10. Willing to use Study IPs, their UB cigarette and UB moist snuff (Study IP Product S) during the study period.\n11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of four Test Sessions.\n12. Females must be willing to use a form of contraception acceptable to an investigator from the time of signing the ICF until End-of-Study.\n\n    Examples of acceptable means of birth control are, but not limited to:\n    1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n    2. physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n    3. abstinence;\n    4. non-hormone releasing intrauterine devices (IUD);\n    5. vasectomized partner; or\n    6. post-menopausal and not on hormone replacement therapy.\n13. Agrees to an in-clinic confinement of five days (four nights).\n14. BMI within 18.0 to 40.0 kg\u002Fm2, inclusive (minimum weight of at least 50.0 kg at Screening)\n\nExclusion Criteria:\n\n1. Allergic to or cannot tolerate mint or wintergreen flavoring agents.\n2. Individuals or their family members that have ongoing litigation with tobacco company(ies).\n3. Have used electronic nicotine delivery system or tobacco heating device within the 30 days prior to screening.\n4. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.\n5. History, presence of, or clinical laboratory test results indicating diabetes.\n6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at an investigator discretion.\n7. History or presence of bleeding or clotting disorders.\n8. Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n9. Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening or at check-in Day 1.\n10. Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C 13.0 g\u002FdL for males at Screening.\n11. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n12. Has positive urine drug screen (UDS) or alcohol test (urine or breath) at Screening or at Check-in to the Assessment Phase (Day 1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in (Day 1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an investigator.\n13. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).\n14. Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Wegovy®, Mounjaro®, and Ozempic®), or lobelia extract within 30 days prior to signing the informed consent.\n15. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.\n16. Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.\n17. Individuals ≥ 35 years of age currently using systemic, testosterone, estrogen-containing contraception or hormone replacement therapy.\n18. Whole blood donation or lost blood or blood products in excess of 500 mL within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day 1.\n19. Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day 1.\n20. Employed by a tobacco or nicotine company, the study site, or handles raw, unpackaged tobacco- or nicotine-containing products as part of their job.\n21. Has used an investigational drug, device, biologic, or tobacco\u002Fnicotine product in a previous clinical study within 30 days or 5 times the half-life of the product (whichever is longer) prior to Screening.\n22. Drinks more than 21 servings of alcoholic beverages per week.\n23. Determined by an investigator to be inappropriate for this study.","60 Years",{"count":180,"type":21},[24],"This is a single-site, open-label, randomized, 4-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics \\[PD\\]) and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during controlled monitored use and following ad libitum use of the study investigational products (IPs) by generally healthy smokers who are also users of smokeless tobacco.",[57,268,28,207],"Smoking Behaviors","2026-05-12",{"date":221,"type":34},{"date":60,"type":21},{"date":273,"type":21},"2026-11-30",{"name":275,"class":67},"RAI Services Company",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":93,"sex":17,"minAge":124,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":148},"100605470","cigar-legislation-and-regulation-in-tobacco-for-the-young-project-clarity-100605470","NCT07162935","Cigar Legislation and Regulation in Tobacco for the Young (Project CLARITY)","Addiction Potential, Flavoring Content, and Substitutability of Concept Flavored Cigarillos","CLARITY","Inclusion Criteria:\n\n1. Ages 18 to 24\n2. Report past 30-day use of a cigarillo\n3. Ability to read English at least an 8th grade level\n4. No immediate plans to quit using tobacco\n5. At least 1 prior experience with a flavored tobacco product\n6. U.S. Citizen or permanent resident of the United States.\n\nExclusion Criteria:\n\n1. Current use of smoking cessation pharmacotherapy or nicotine replacement therapy;\n2. Pregnant, planning to become pregnant, or currently breastfeeding;\n3. Past or current clinically significant heart disease or hypertension, or other smoking-related disease that could preclude successful study completion;\n4. Inability to abstain from nicotine\u002Ftobacco products for at least 12 hours\n5. Unwillingness to use the research cigarillos in the lab","24 Years",{"count":286,"type":21},300,[24],"This clinical trial will recruit young adults who currently use cigarillos and examine the smoking behavior and perceptions of different flavored cigarillos, product ingredients\u002Fadditives impacting these perceptions, and simulated tobacco use outcomes (quitting, switching) in various policy scenarios where different types of flavors are available on the market.",[290,28],"Cigar Smoking","2026-05-07",{"date":293,"type":34},"2026-05-11",{"date":295,"type":34},"2026-02-23",{"date":297,"type":21},"2030-05-31",{"name":299,"class":41},"University of Oklahoma",{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":93,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":317,"locationsCount":42},"100483256","linking-brain-network-dynamics-to-imminent-smoking-lapse-risk-and-behavior-100483256","NCT05572671","Linking Brain Network Dynamics to Imminent Smoking Lapse Risk and Behavior","Inclusion Criteria:\n\n* Participants must be between the ages of 21 and 65.\n* Participants must be fluent English speakers.\n* Participants must pass an MRI safety screening.\n* Participants must report smoking at least six cigarettes per day continuously for at least the 12 preceding months.\n* Participants must have a baseline expired-air carbon monoxide exceeding 10 parts per million in order to verify smoking status.\n\nExclusion Criteria:\n\n* Individuals will be excluded if they report that they are not willing to refrain from using nicotine for 12 hours before the experimental lab visit.\n* Individuals will be excluded if they have any known risk from exposure to high-field strength magnetic fields (e.g., pacemakers), any irremovable metallic foreign objects in their body (e.g., braces), or a questionable history of metallic fragments that are likely to create artifact on the MRI scans.",{"count":307,"type":21},150,[24],"Most attempts to quit smoking end in relapse, or a return to regular smoking. One of the biggest threats to cessation is a lapse (i.e., any cigarette use during a quit attempt). Thus, characterizing why lapses occur is essential to understanding and preventing smoking relapse. Functional magnetic resonance imaging (fMRI) is a promising method for characterizing the psychological processes that lead to smoking lapses because it provides a way to measures patterns of brain activity thought to reflect relevant mental processes as they change over time. However, methodological issues have hindered the ability to capitalize on this potential and prevented an understanding of how brain activity and corresponding psychological processes unfold in the critical moments that immediately precede a smoking lapse. The proposed project will address this knowledge gap using a novel fMRI paradigm adapted from a well-validated behavioral lapse task. The goals of the project are to characterize changes in brain activity that lead up to a lapse and to investigate how these changes are related to concurrent affect and subsequent cigarette use.",[57,28],"2026-04-29",{"date":313,"type":34},"2026-05-05",{"date":315,"type":34},"2023-04-04",{"date":145,"type":21},{"name":318,"class":41},"Penn State University",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":17,"minAge":124,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":328,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":148},"100518673","phase-3-motivational-interviewing-and-mindfulness-oriented-recovery-enhancement-100518673","NCT06033599","Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement","Motivational Interviewing (MI) and Mindfulness-Oriented Recovery Enhancement (MORE) for Tobacco Dependence and Other Drug Use in Methadone Treatment","Inclusion Criteria:\n\n* English-speaking\n* Age ≥18\n* Currently on methadone; and 4) currently smoke cigarettes.\n\nExclusion Criteria:\n\n* Severe cognitive impairment (score \\>23 on Mini Mental Status Exam) or psychosis (positive SCID Psychotic Screen)\n* Suicidal risk (score ≥7 on Suicidal Behaviors Questionnaire)\n* Inability to attend or fully participate in intervention sessions or assessments\n* Previous formal mindfulness training (e.g., MBSR, MBRP) or MORE (from the R21 or R33\n* Currently taking smoking cessation pharmacotherapy or participating in smoking cessation counseling\n* Any contraindications for NRT\n* Currently or soon planning to be pregnant or breastfeeding.",{"count":327,"type":21},420,[329],"PHASE3","The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient outcomes related to the effectiveness of MORE decreasing opioid, tobacco, and other drug use.",[332,333,28],"Polysubstance Abuse","Opioid Use","2026-04-27",{"date":336,"type":34},"2026-04-28",{"date":338,"type":34},"2023-09-05",{"date":340,"type":21},"2028-06-30",{"name":342,"class":41},"Rutgers, The State University of New Jersey",{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":93,"sex":17,"minAge":50,"maxAge":349,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":42},"100488638","trial-of-a-harm-reduction-strategy-for-people-with-hiv-who-smoke-cigarettes-100488638","NCT05642715","Trial of a Harm Reduction Strategy for People With HIV Who Smoke Cigarettes","Inclusion Criteria:\n\n1. Age 40-79 (the ACC\u002FAHA PCEs risk score is only valid in this age range).\n2. Current cigarette smoking (\"Yes\" to: \"Have you smoked more than 100 cigarettes in your lifetime?\" AND \"Have you smoked a cigarette, even a puff, in the past 7 days?\"\n3. Lab-confirmed HIV infection\n4. Willingness to participate in a web-based tobacco treatment (EX+) AND offer of varenicline\n5. Access to internet at least weekly and ability to read at ≥7th grade level (necessary to participate fully in EX+ program).\n6. Willingness to be randomized to one of the two study conditions\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Lack of insurance for specialty referral (we expect this exclusion to be rare because the great majority of people with HIV (PWH) at the Montefiore Medical Center have Medicaid or AIDS Drug Assistance Program (ADAP)\n3. Contraindication to varenicline\n4. Concurrent receipt of other cessation treatments\n5. Evaluation in Cardiometabolic Clinic within the 12 months prior to enrollment\n6. To minimize study contamination, eligible individuals who are spouses, partners, or roommates of participants will be excluded","79 Years",{"count":351,"type":21},400,[24],"Cigarette smoking is now the leading killer of people with HIV (PWH) in the US, and most cessation strategies tried to date have failed to increase long-term quit rates. An \"all or none\" approach to smoking cessation in PWH offers little benefit to the large majority of PWH who are unable or unwilling to quit. In this proposal we argue that a harm reduction approach (i.e., cut down, get screened for lung cancer, control your blood pressure and cholesterol) has the potential to yield significant benefits in terms of the private and public health of PWH in the US.",[355,28],"Hiv",[357,358,359,57,360],"HIV","Tobacco","Cigarette","Harm reduction","2026-04-17",{"date":363,"type":34},"2026-04-21",{"date":365,"type":34},"2024-04-04",{"date":367,"type":21},"2027-03",{"name":369,"class":41},"Montefiore Medical Center",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":93,"sex":17,"minAge":377,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":382,"conditions":383,"keywords":384,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":148},"100431816","rtms-targets-neural-circuits-for-smoking-cessation-100431816","NCT04903028","RTMS Targets Neural Circuits for Smoking Cessation","RTMS Manipulates Imbalanced Drive-reward and Executive Control Circuitry for Smoking Cessation","Inclusion Criteria\n\n* Be between the ages of 22 and 70 years old.\n* Smoke 10 or more cigarettes per day and have a carbon monoxide (CO) level \\> 10 ppm indicative of recent smoking.\n* Have not received substance abuse treatment within the previous 30 days.\n* Meet the criteria for tobacco use disorder as determined by DSM-5.\n* Be in stable mental and physical health.\n* If female, test non-pregnant and use adequate birth control.\n* Show no evidence of focal or diffuse brain lesions on MRI.\n* Be willing to provide informed consent.\n* Be able to comply with protocol requirements and likely to complete all study procedures.\n* Be motivated to quit smoking (based on responses of \"very likely,\" or \"somewhat likely\" in the motivation questionnaire).\n\nExclusion Criteria\n\n* Current moderate to severe substance use of any psychoactive substances other than nicotine or caffeine, as defined by DSM-V criteria.\n* Contraindications to MRI (e.g., presence of metal in the skull, orbital or intracranial cavity, or having claustrophobia).\n* Contraindication to rTMS.\n* History of autoimmune, endocrine, viral, or vascular disorders affecting the brain.\n* History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment.\n* Unstable cardiac disease, uncontrolled hypertension, severe renal or liver insufficiency, or sleep apnea.\n* Lifetime history of major Axis I disorders such as: bipolar affective disorder (BPAD), schizophrenia, post-traumatic stress disorder (PTSD), dementia, suicidal ideation or major depression.\n* Self-report of \\>21 standard alcohol drinks per week in any week in the 30 days prior to screening.\n* Use of other forms of nicotine delivery, such as nicotine patches, electronic cigarettes, gum, nasal spray, inhalers, and nicotine lozenges.\n* Use of other tobacco products, including cigars, cigarillos, chew, snuff, and pouches\u002Fsnus.\n* Previous treatment with TMS.","22 Years","70 Years",{"count":380,"type":21},64,[24],"Cigarette smoking is a significant public health concern. Transcranial magnetic stimulation (TMS) is a non-invasive form of brain stimulation that has already displayed remarkable potential for producing novel, non-pharmacological interventions for depression and cigarette smokers. In this study, investigators will use brain MRI to guide TMS therapy for smoking cessation.",[28,99],[385],"Tobacco use disorder, rTMS, smoking cessation","2026-04-13",{"date":388,"type":34},"2026-04-16",{"date":390,"type":34},"2021-05-15",{"date":392,"type":21},"2027-04-04",{"name":394,"class":41},"Medical University of South Carolina",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":93,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":406,"conditions":407,"keywords":410,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":42},"100562895","phase-1-effect-of-cannabis-on-e-cigarette-use-behavior-100562895","NCT06609109","Effect of Cannabis on E-Cigarette Use Behavior","Effect of Cannabinoids on Tobacco Product Demand and Pharmacodynamics: Electronic Cigarette Use","Inclusion criteria:\n\n1. Healthy non-treatment seeking adults aged 21 or older\n2. Report daily use of e-cigarettes\n3. Biological confirmation of e-cigarette use: have a positive urine cotinine test at screening\n4. Report current use of cannabis (at least 1 occasion per week)\n5. Have experience with the inhalation route of administration for cannabis\n6. Biological confirmation of cannabis use: have a positive urinary THC drug test at screening.\n7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study.\n\nExclusion criteria:\n\n1. Report current intention to reduce or quit cannabis or tobacco use within the next 30 days\n2. Meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine\n3. Test positive for illicit drugs other than cannabis and tobacco\n4. Positive breath alcohol test at study admission\n5. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity\n6. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n7. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding\n8. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina)\n9. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.",{"count":403,"type":21},100,[405],"PHASE1","The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of electronic cigarettes. The study's goals are to test demand for e-cigarettes, tobacco craving, affect, heart rate, blood pressure, expired breath carbon monoxide, and cognitive performance. Researchers will compare multiple doses of THC and a placebo in participants who smoke e-cigarettes and either smoke or vape THC in the laboratory.",[408,28,409],"Cannabis Use","Electronic Cigarette Use",[411,412,413,414,415,358],"cannabis","e-cigarette","electronic cigarette","marijuana","THC","2026-04-08",{"date":418,"type":34},"2026-04-09",{"date":420,"type":34},"2025-03-19",{"date":422,"type":21},"2029-10-01",{"name":424,"class":41},"Johns Hopkins University",{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":17,"minAge":124,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":436,"conditions":437,"keywords":440,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":42},"100610643","telegram-messenger-support-for-smoking-cessation-after-heart-attack-100610643","NCT07230249","Telegram Messenger Support for Smoking Cessation After Heart Attack","Effect of a Behavioral Intervention Delivered Via Telegram Messenger on Smoking Cessation in Patients After Myocardial Infarction: The TELEGRAM-MI Randomized Controlled Trial","TELEGRAM-MI","Inclusion Criteria:\n\n* Willing and able to provide written informed consent.\n* Age 18 years or older.\n* Hospitalization with a confirmed diagnosis of acute myocardial infarction (MI), including both ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI).\n* Current smoker at the time of index MI: self-reported smoking of at least one cigarette per day in the month prior to hospitalization.\n* Regular user of the Telegram messenger application (app installed on a personal smartphone).\n* Possession of a smartphone with internet access and a valid phone number.\n* Ability and willingness to provide contact information for a close relative or cohabiting person who can verify smoking status at follow-up.\n\nExclusion Criteria:\n\n* Smoking cessation more than 1 month prior to the index MI hospitalization.\n* Physical or cognitive impairment that prevents the use of a smartphone (e.g., severe visual\u002Fhearing impairment, inability to read or respond to messages).\n* Inability to read and understand the Russian language fluently.\n* Comorbid condition with a life expectancy of less than 1 year.\n* Active severe mental illness (e.g., psychosis, severe untreated depression) that would impede understanding of the protocol or adherence.\n* Unwillingness or inability to provide contact details for a close relative for outcome verification.",{"count":434,"type":21},142,[24],"This randomized controlled trial will evaluate whether a 6-month behavioral intervention delivered via Telegram messenger increases smoking cessation rates in patients after myocardial infarction (MI).\n\nAdult smokers hospitalized with acute MI who regularly use Telegram will be randomly assigned to either:\n\n* INTERVENTION GROUP: Standard care plus a 6-month Telegram chatbot program providing personalized motivational messages, cognitive-behavioral techniques for craving management, and relapse prevention support.\n* CONTROL GROUP: Standard care (routine physician advice to quit smoking) plus basic surveys via Telegram without therapeutic content.\n\nThe primary outcome is 30-day point prevalence abstinence at 6 months, verified by blinded telephone interview with participant and corroborating report from a close relative. Secondary outcomes include changes in cigarette consumption, nicotine dependence, motivation, and intervention engagement metrics.\n\nThis study addresses the critical gap in smoking cessation support after hospital discharge and could provide evidence for a scalable digital health solution in cardiac secondary prevention.",[438,28,439],"Myocardial Infarction (MI)","Smoking Cessation",[441,442,443,444,445,446,447],"Telegram","Chatbot","Digital Health","Behavioral Intervention","Secondary Prevention","Randomized Controlled Trial","Cardiac Rehabilitation","2026-04-02",{"date":450,"type":34},"2026-04-03",{"date":452,"type":21},"2026-05-01",{"date":454,"type":21},"2027-01-01",{"name":456,"class":41},"ITMO University",{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":93,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":477},"100586994","steps-substance-use-trial-of-e-cigarettes-or-pharmacotherapy-for-smoking-100586994","NCT06922617","STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking","Evaluating a Tobacco Harm Reduction Strategy Among Clients Enrolled in Substance Use Disorder Treatment","STEPS","Inclusion Criteria:\n\n1. 21+ years of age,\n2. smoke at least 5 cigarettes per day daily or near daily for the past 6 months,\n3. be enrolled in outpatient SUD treatment and have an SUD diagnosis (past or current),\n4. must submit a breath CO sample of ≥ 7 parts per million at screening and a positive instant-read urinary cotinine test,\n5. have had at least one failed smoking quit attempt in their lifetime,\n6. have interest in reducing smoking, quitting smoking, or switching to a less harmful product, and\n7. if female, agrees to use a form of birth control during the study.\n\nExclusion criteria:\n\n1. any significant or unstable medical or psychiatric concern that would affect safety,\n2. current use of pharmacotherapy with smoking cessation efficacy,\n3. pregnant, breastfeeding, or trying to become pregnant,\n4. contraindicated for NRT, and\n5. currently using an ENDS on 20+ days out of the past 30.",{"count":466,"type":21},240,[24],"The purpose of this study is to investigate whether non-cigarette tobacco products, namely e-cigarettes (nicotine vapes), can help people who smoke and are in treatment for substance use disorder quit smoking by switching completely to e-cigarettes as compared to FDA-approved medications, namely nicotine replacement therapy in the form of patches and lozenges. Participation will last 6 months and will include five in-person study visits and eleven virtual assessments. Participants will also complete a short daily diary on their phones each day for the first twelve weeks. To qualify, participants must be within 30 days of SUD treatment program admission. This study is being conducted at three outpatient SUD treatment programs across South Carolina. These sites include: 1) the Center for Drug and Alcohol Problems (CDAP) in Charleston, SC, 2) Behavioral Health Services of Pickens County (BHSPC) in Pickens, SC, and 3) Shoreline Behavioral Health Services in Conway, SC. the Medical University of South Carolina in Charleston, SC, Behavioral Health Services in Pickens, SC, and the Medical University of South Carolina in Florence, SC.",[28,470],"Substance Use Disorders",{"date":450,"type":34},{"date":473,"type":34},"2025-10-17",{"date":475,"type":21},"2028-09-01",{"name":394,"class":41},4,{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":124,"maxAge":284,"enrollmentInfo":485,"targetDuration":4,"studyType":22,"phases":487,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":42},"100632584","a-mindfulness-based-intervention-for-sexual-assault-survivors-100632584","NCT07515586","A Mindfulness-based Intervention for Sexual Assault Survivors","Leveraging Implementation Science to Develop a Mindfulness-Based Intervention to Reduce Alcohol Misuse and Tobacco Use Among Sexual Violence Survivors","Inclusion Criteria:\n\n* 18-24 years of age\n* currently enrolled as a full-time undergraduate at GSU\n* self-reported lifetime SV victimization\n* self-reported SV victimization in the past 6 months\n* drank alcohol within the last 30 days\n* must own a smartphone\n\nExclusion Criteria:\n\n* not applicable",{"count":486,"type":21},120,[24],"The goal is this pilot randomized trial is to learn if intervention 1 is feasible and acceptable. As a secondary goal, we aim to learn if intervention 1 reduces alcohol misuse and tobacco use in sexual assault survivors. The main questions it aims to answer are:\n\n* Is intervention 1 feasible to implement?\n* Is intervention 1 an acceptable intervention among the primary population, sexual assault survivors?\n* Does intervention 1 reduce alcohol misuse and tobacco use?\n\nResearchers will compare intervention 1 to an attention-placebo control group (e.g., online resources on healthy eating and nutrition).\n\nParticipants will:\n\n* take online surveys at baseline, 1 month follow-up, and 3-month follow-up\n* answer text-message questions at baseline and post-test\n* view and engage in an educational program",[490,28,491,492],"Alcohol Misuse","Mindfulness","Stress","2026-03-31",{"date":495,"type":34},"2026-04-07",{"date":497,"type":21},"2027-10",{"date":499,"type":21},"2030-08",{"name":501,"class":41},"Georgia State University",{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":123,"minAge":124,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":22,"phases":511,"briefSummary":512,"conditions":513,"keywords":515,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":527,"locationsCount":42},"100630574","feasibility-and-acceptability-trial-to-reduce-tobacco-and-cannabis-use-during-pregnancy-and-postpartum-100630574","NCT07489443","Feasibility and Acceptability Trial to Reduce Tobacco and Cannabis Use During Pregnancy and Postpartum","Partnering With Pregnant and Postpartum People to Co-Create a Novel Intervention to Reduce Tobacco and Cannabis Use","PICTURe","Inclusion Criteria:\n\n* Confirmed pregnant\n* Under 26 weeks gestation\n* Plan to remain pregnant\n* English speaking\n* Use of combustible tobacco at least once a week during pregnancy, or at least once a week in the 3 months before pregnancy if stopped\n* Use of cannabis at any frequency during pregnancy or in the 3 months before pregnancy if stopped\n\nExclusion Criteria:\n\n* Current opioid use or active treatment for Opioid Use Disorder\n* Unable to provide informed consent in English\n* Under 18 years old",{"count":7,"type":21},[24],"Using both tobacco and cannabis during pregnancy is more common in minoritized groups and can make quitting smoking in pregnancy and remaining smoke free postpartum difficult. Investigators will test an intervention to address prenatal depressive symptoms to encourage people to quit tobacco and cannabis during pregnancy and stay quit postpartum.",[514,408,28,439],"Perinatal",[245,516,517,211,518,519,411,520],"perinatal","pregnancy","cessation","postpartum","intervention","2026-03-17",{"date":523,"type":34},"2026-03-24",{"date":525,"type":21},"2026-04",{"date":497,"type":21},{"name":528,"class":41},"University of Pittsburgh",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":93,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":22,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":42},"100544746","noncombustible-nicotine-delivery-systems-as-potential-harm-reduction-tools-for-persistent-cigarette-smokers-100544746","NCT06372899","Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers","Alternative Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers","Inclusion Criteria:\n\n1. Able to communicate fluently in English (i.e. speaking, writing, and reading)\n2. Male and female smokers who are \\> 21 years of age and self-report smoking at least 5 cigarettes (menthol and\u002For non-menthol) per day for at least the last 6 months.\n3. 5 or more failed quit attempts and the use of smoking cessation medication on at least one prior attempt.\n4. Have a carbon monoxide (CO) greater than 10 ppm.\n5. Not using any forms of nicotine regularly other than cigarettes\n6. Be willing to switch to e-cigarettes or nicotine pouches for 6 weeks.\n7. Plan to live in the area for the duration of the study.\n8. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.\n\nExclusion Criteria:\n\nSmoking Behavior\n\n1. Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, etc.). Regular e-cigarette and nicotine pouch use is defined as greater than 5 days\u002Fpast 30 days.\n\n   a. Participants agreeing to abstain from using nicotine-containing products other than cigarettes for the duration of the study will be considered eligible.\n2. Current enrollment or plans to enroll in a smoking cessation program over the duration of the study.\n3. Current use of smoking cessation medication\n4. Provide a CO breath test reading less than 10 ppm at Intake.\n\nAlcohol and Drug\n\n1. History of substance abuse (other than nicotine dependence) in the past 12 months.\n2. Current alcohol consumption that exceeds 20 standard drinks\u002Fweek.\n3. Current use of recreational drugs (other than nicotine and cannabis)\n4. Breath alcohol reading (BrAC) greater than .000 at Intake.\n\nMedical\n\n1. Women, including all individuals assigned as \"female\" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.\n2. Serious or unstable disease within the past year (e.g. cancer, heart disease). Applicable conditions will be evaluated on a case-by-case basis by the Principal Investigator.\n\nPsychiatric\n\n1\\. Lifetime history of schizophrenia or psychosis.\n\nGeneral Exclusion\n\n1. Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and\u002For the study design as determined by the Principal Investigator.\n2. Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.\n3. Significant non-compliance with protocol and\u002For study design as determined by the Principal Investigator. Subjects may be deemed ineligible at any point throughout the study.",{"count":537,"type":21},200,[24],"This between-subjects study aims to evaluate whether e-cigarettes (ECIGS) versus oral nicotine pouches (ONPS) more readily substitute for combustible cigarettes among 200 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to ECIGS or ONPS and be instructed to switch (versus smoking cigarettes) over a 6-week period. Relative reductions in biomarkers of exposure will be measured. ECIG- and ONP-associated subjective reward and the reinforcing value of ECIGS and ONPS relative to combustible cigarettes will be assessed as mechanisms.",[541,99,542,28],"E-cigarette Use","Harm Reduction","2026-03-11",{"date":545,"type":34},"2026-03-12",{"date":547,"type":34},"2024-10-02",{"date":549,"type":21},"2028-03-31",{"name":114,"class":41},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":124,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":22,"phases":561,"briefSummary":562,"conditions":563,"keywords":570,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":42},"100627340","clinical-management-of-cardiovascular-risk-factors-in-adult-patients-a-before-and-after-interventional-study-100627340","NCT07447362","Clinical Management of Cardiovascular Risk Factors in Adult Patients: A Before-and-After Interventional Study","Effect of a Structured Clinical and Pharmacological Management Strategy on Cardiovascular Risk Factors in Adult Patients in Routine Clinical Practice: A Pseudo-Experimental Before-and-After Study","CV-RISK","Inclusion Criteria:\n\n* Age ≥18 years\n* Presence of at least one cardiovascular risk factor (hypertension, diabetes, dyslipidemia, obesity, or smoking)\n* Receiving outpatient clinical follow-up\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe clinical instability requiring hospitalization\n* Pregnancy\n* End-stage renal disease or dialysis\n* Inability to complete follow-up visits\n* Refusal to participate",{"count":560,"type":21},220,[24],"This study aims to evaluate cardiovascular risk factors, clinical characteristics, and outcomes in adult patients attending an outpatient cardiology clinic. The research focuses on identifying predictors of adverse cardiovascular events, optimizing risk stratification, and improving preventive strategies in routine clinical practice. Data will be collected from patients receiving standard cardiology care without altering their treatment. The results are expected to contribute to better understanding of cardiovascular risk profiles and to support improvements in clinical decision-making and patient management.",[564,565,566,567,568,569,28],"Cardiovascular Risk Factors","Hypertension","Dyslipidemia","Type 2 Diabetes Mellitus","Obesity","Overweight",[571,572,573,574],"Cardiovascular prevention","Risk factor control","Medication adherence","Clinical follow-up","2026-02-27",{"date":577,"type":34},"2026-03-03",{"date":579,"type":34},"2024-07-24",{"date":581,"type":21},"2026-10-24",{"name":583,"class":41},"Universidad Católica San Antonio de Murcia",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":93,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":592,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":42},"100536386","the-role-of-flavor-in-the-substitutability-of-e-cigarettes-for-combustible-cigarettes-among-persistent-smokers-100536386","NCT06264154","The Role of Flavor in the Substitutability of E-cigarettes for Combustible Cigarettes Among Persistent Smokers","Inclusion Criteria:\n\n1. Able to communicate fluently in English (i.e. speaking, writing, and reading)\n2. Male and female smokers who are \\> 21 years of age and self-report smoking at least 5 cigarettes (menthol and\u002For non-menthol) per day for at least the last 12 months\n3. 5 or more failed quit attempts and the use of smoking cessation medication on at least one prior attempt.\n4. Ever use of an e-cigarette\n5. Have a carbon monoxide (CO) greater than 10 ppm\n6. Not using any forms of nicotine regularly other than cigarettes\n7. Be willing to switch to e-cigarettes for 6 weeks and use the assigned flavors\n8. Plan to live in the area for the duration of the study\n9. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.\n\nExclusion Criteria:\n\nSmoking Behavior Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, etc.). Regular e-cigarette use is defined as greater than 5 days\u002Fpast 30 days\n\n1. Participants agreeing to abstain from using nicotine-containing products other than cigarettes for the duration of the study will be considered eligible.\n2. Current enrollment or plans to enroll in a smoking cessation program over the duration of the study.\n3. Current use of smoking cessation medication\n4. Provide a CO breath test reading less than 10 ppm at Intake.\n\nAlcohol and Drug\n\n1. History of substance abuse (other than nicotine dependence) in the past 12 months.\n2. Current alcohol consumption that exceeds 20 standard drinks\u002Fweek.\n3. Current use of recreational drugs (other than nicotine and cannabis)\n4. Breath alcohol reading (BrAC) greater than .000 at Intake.\n\nMedical\n\n1. Women, including all individuals assigned as \"female\" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.\n2. Serious or unstable disease within the past year (e.g. cancer, heart disease). Applicable conditions will be evaluated on a case-by-case basis by the Principal Investigator.\n3. Allergies to either propylene glycol or flavor additives\n\nPsychiatric\n\n1\\. Lifetime history of schizophrenia or psychosis.\n\nGeneral Exclusion\n\n1. Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and\u002For the study design as determined by the Principal Investigator.\n2. Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.\n3. Significant non-compliance with protocol and\u002For study design as determined by the Principal Investigator and\u002Fo. Subjects may be deemed ineligible at any point throughout the study.",{"count":591,"type":21},210,[24],"This between-subjects study aims to evaluate the effect of flavor on initial and sustained switching from combustible cigarettes to e-cigarettes among 210 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to a six-week regimen of fruit-flavored, tobacco-flavored, or menthol-flavored e-cigarettes and be instructed to switch (versus smoking cigarettes) over a 6-week period. Flavor-associated subjective reward and the reinforcing value of flavored e-cigarettes relative to combustible cigarettes will be assessed as mechanisms.",[57,28,99,595],"E-Cig Use","2026-02-17",{"date":598,"type":34},"2026-02-19",{"date":600,"type":34},"2024-08-26",{"date":602,"type":21},"2027-12",{"name":114,"class":41},{"id":605,"slug":4,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":93,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":22,"phases":611,"briefSummary":612,"conditions":613,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":42},"100538816","NCT06295757","Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures","Inclusion Criteria:\n\n* Smoking at least 10 cigarettes\u002Fday for at least 1 year (confirmed by CO \\> 8 ppm or NicAlert test of 6)\n* Engaging in relighting for at least half of their CPD\n* No smoking quit attempts in the past month nor intentions to quit in the next month\n* Stable medical or psychiatric conditions with systolic blood pressure \\\u003C 160, diastolic blood pressure \\\u003C 100 and heart rate \\\u003C 105 bpm\n\nExclusion Criteria:\n\n* Participant with current or recent alcohol or drug abuse problems, use of substances of abuse (other than marijuana due to high prevalence of co-use) within the past month\n* Currently trying or planning to quit smoking in the next month\n* Planning to become pregnant, pregnant or breastfeeding. Pregnancy exclusion will be confirmed through a urine test.",{"count":610,"type":21},30,[24],"Characterize effects of relighting on smoke toxicant deliveries and subjective smoking measures. This will be a within-subject comparison in a single experimental group of 30 smokers who report engaging in relighting behaviors. We will assess smoking intensity for relit and non-relit (i.e., smoked continuously without relighting) cigarettes in the natural environment and will conduct in-clinic measurements of smoking topography and subjective responses for relit and non-relit cigarettes. Information on relighting patterns and smoking topography collected from each participant will be used to compare machine-measured smoke yields of key harmful constituents when their usual cigarettes are smoked with and without relighting. Hypothesis: Relit cigarettes will produce higher levels of toxicants than non-relit cigarettes.",[28,99,614],"Nicotine Dependence","2026-02-02",{"date":617,"type":34},"2026-02-04",{"date":619,"type":34},"2024-10-12",{"date":621,"type":21},"2028-01-01",{"name":623,"class":41},"Masonic Cancer Center, University of Minnesota",{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":93,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":631,"targetDuration":4,"studyType":22,"phases":632,"briefSummary":633,"conditions":634,"keywords":635,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":643,"locationsCount":42},"100562893","phase-1-effect-of-cannabis-on-cigarette-use-behavior-100562893","NCT06609083","Effect of Cannabis on Cigarette Use Behavior","Effect of Cannabinoids on Tobacco Product Demand and Pharmacodynamics: Cigarette Use","Inclusion Criteria:\n\n1. Healthy non-treatment seeking adults aged 21 or older\n2. Report daily use of combustible tobacco cigarettes\n3. Biological confirmation of cigarette use: have an expired carbon monoxide (CO) level of more than 5 ppm and a positive urine cotinine test at screening\n4. Report current use of cannabis (at least 1 occasion per week)\n5. Have experience with the inhalation route of administration for cannabis\n6. Biological confirmation of cannabis use: have a positive urinary THC drug test at screening.\n7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study.\n\nExclusion Criteria:\n\n1. Report current intention to reduce or quit cannabis or tobacco use within the next 30 days\n2. Meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine\n3. Test positive for illicit drugs other than cannabis and tobacco\n4. Positive breath alcohol test at study admission\n5. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity\n6. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n7. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding\n8. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina)\n9. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.",{"count":403,"type":21},[405],"The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of cigarettes. The study's goals are to test demand for cigarettes, tobacco craving, affect, heart rate, blood pressure, expired breath carbon monoxide, and cognitive performance. Researchers will compare multiple doses of THC and a placebo in participants who smoke cigarettes and either smoke or vape THC in the laboratory.",[408,28,99],[411,636,414,415,245],"cigarette","2026-01-15",{"date":639,"type":34},"2026-01-16",{"date":641,"type":34},"2025-01-22",{"date":422,"type":21},{"name":424,"class":41}]